New York, NY, May 22, 2023 – A2A Pharmaceuticals, a clinical-stage biopharmaceutical company, announced FDA clearance for their Investigational New Drug (IND) application to begin a Phase I trial of AO-252, an investigational TACC3 Protein-Protein Interaction (PPI) inhibitor, in adult patients with high-grade serious ovarian (HGSOC), triple-negative breast (TNBC), and endometrial cancers. Dr. Sotirios Stergiopoulos expressed gratitude to the FDA for this milestone, highlighting the goal to address the unmet medical need for treating aggressive cancers. This represents a significant achievement for A2A Pharmaceuticals and their collaborators at Oncocube.
